SuperworthSpero Therapeutics PE ratio SPRO
Share price divided by earnings per share over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 10.1×
- 3-year median
- 9.5×
- Against its 3-year history
- 52nd
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 3.0× to 22.9×
- Peer median
- 11.3×
Spero Therapeutics' PE ratio is 10.1× as of Oct 23, 2026: a share price of $1.11 against $0.11 of earnings per share over the last twelve months.
That is above its 3-year median of 9.5×, close to the middle of its last 3 years.
Over that time it ranged from 3.0× in Jun 2024 to 22.9× in Apr 2026.
The median for 8 large drugmakers of a similar size is 11.3×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 10.1× | 4.9× | 22.9× |
| 2025 | 11.7× | 11.1× | 15.7× |
| 2024 | 14.7× | 3.0× | 16.9× |
Against its peers
Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.
| Company | PE ratio |
|---|---|
| SPROSpero Therapeutics | 10.1× |
| LFVNLifevantage | 14.7× |
| ATNMActinium Pharmaceuticals | 4.2× |
| NATRNatures Sunshine Products | 12.0× |
| ARVNArvinas | 45.6× |
| PBYIPuma Biotechnology | 21.2× |
| IRWDIronwood Pharmaceuticals | 4.5× |
| ZVRAZevra Therapeutics | 10.5× |
| CRMDCorMedix | 3.7× |
| Peer median | 11.3× |
Where Spero Therapeutics ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Spero Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.